Showing 2631-2640 of 2839 results for "".
- Art Lesson Teaches Plastic Surgeons Better Botox Injection Techniqueshttps://modernaesthetics.com/news/art-lesson-teaches-plastic-surgeons-better-botox-injection-techniques-facebookshare-to/2472207/A highly detailed body painting project helps plastic surgeons understand how underlying muscles contribute to facial lines and wrinkles as well as how to better treat them using botulinum toxin injections. The illustrated article, which appears in Plas
- Bonti's Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://modernaesthetics.com/news/bontis-gateway-neuromodulator-performs-well-in-pase-2a-for-glabellar-lines/2472208/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serot
- USA, Brazil Take the Lead for Most Plastic Surgery Procedureshttps://modernaesthetics.com/news/usa-brazil-take-the-lead-for-most-plastic-surgery-procedures/2472215/Plastic surgery is on the rise across the globe, according to new statistics from The International Society of Aesthetic Plastic Surgery (ISAPS). There was an overall increase of 9 percent in surgical and non-surgical cosmetic procedures in 2016.
- Neothetics, Inc.'s Stock Tumbles Following "Unambiguous" Negative LIPO-202 Resultshttps://modernaesthetics.com/news/neothetics-incs-stock-tumbles-following-unambiguous-negative-lipo-202-results/2472217/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares d
- There's a New Pico in Town: Wontech's Picocare Scores FDA Nodhttps://modernaesthetics.com/news/theres-a-new-pico-in-town-wontechs-picocare-scores-fda-nod/2472218/The U.S. Food and Drug Administration (FDA) cleared WONTECH’s picosecond laser device for tattoo removal. PICOCARE removes tattoos in various colors in less time with 1064nm, 532nm, 595nm, and 660nm wavelengths and selectively removes pigment par
- Sculpture OK'd for Back, Inner and Outer Thighshttps://modernaesthetics.com/news/sculpsure-oked-for-back-inner-and-outer-thighs/2472220/The U.S. Food and Drug Administration (FDA) granted an expanded clearance for Cynosure's SculpSure to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdom
- Nearly 10.5 Million Treatments Performed by ASDS Members in 2016https://modernaesthetics.com/news/nearly-105-million-treatments-performed-by-asds-members-in-2016/2472226/Dermatologic surgeons performed nearly 10.5 million medically necessary and cosmetic procedures in 2016 – five percent more than 2015 and up 31 percent since 2012, according to the 2016 American Society for Dermatologic Surgery (ASDS) Survey on D
- Read Their Lips: Avoid Unnatural Lip Enhancement Results With This Datahttps://modernaesthetics.com/news/read-their-lips-avoid-unnatural-lip-enhancement-results-with-this-data/2472247/Many a Real Housewife from Bravo’s hit reality TV franchise have been chastised for trout pout – or an overfilled, unnatural looking pucker. And now a new study, published by JAMA Facial
- Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studieshttps://modernaesthetics.com/news/restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit-in-phase-4-studies/2472251/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Breaking Business News: Apax Partners to Acquire Syneronhttps://modernaesthetics.com/news/breaking-business-news-apax-partner-to-acquire-syneron/2472253/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price represe